Compare MasTec Inc (MTZ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Tango Therapeutics Inc. — how do they compare? MasTec Inc trades at $191.9 (market cap $16.55B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: MasTec Inc is far larger — about 4.4× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 25 Days and Tango Therapeutics Inc. for 0 Days on average.
| MTZ | TNGX | |
|---|---|---|
Market Cap | $16.55B | $3.75B |
Volume | 1,530,865 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $437.51 | $32.90 |
52-Week Low | $190.08 | $7.50 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $19.47B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $206.12, down 0.35% on the day, with technical indicators showing bearish momentum below key moving averages. The company reported strong revenue growth from $14.3B in 2025 to $16.1B in 2026, with net income improving to $494M. Recent news highlights MTZ's record $21.4B backlog and positioning in AI infrastructure and power delivery markets, though cash flow volatility and premium valuation pose challenges.
Wall Street maintains strong bullish sentiment with 89% buy ratings and a $403.92 consensus price target, representing 96% upside potential. Key opportunities include infrastructure investment cycles and data center expansion, while risks include execution challenges, communications segment softness, and elevated P/E ratio of 32.8x.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
